Report Information More information from: https ://www.wis eguyreports .com/reports /495877
Macular Edema - Pipeline Review, H1 2016 Report / Search Code: WGR495877
Price
1-user P DF : $ 2000.0
Description:
Publish Date: 11 May, 2016
Site P DF : $ 4000.0
Enterprise P DF : $ 6000.0
Macular Edema - Pipeline Review, H1 2016 Summary Global Markets Direct’s , ‘Macular Edema - Pipeline Review, H1 2016’, provides an overview of the Macular Edema pipeline lands cape. The report provides comprehens ive information on the therapeutics under development for Macular Edema, complete with analys is by s tage of development, drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type. The report als o covers the des criptive pharmacological action of the therapeutics , its complete res earch and development his tory and lates t news and pres s releas es . Additionally, the report provides an overview of key players involved in therapeutic development for Macular Edema and features dormant and dis continued projects . Global Markets Direct’s report features inves tigational drugs from acros s globe covering over 20 therapy areas and nearly 3,000 indications . The report is built us ing data and information s ourced from Global Markets Direct’s proprietary databas es , company/univers ity webs ites , clinical trial regis tries , conferences , SEC filings , inves tor pres entations and featured pres s releas es from company/univers ity s ites and indus try-s pecific third party s ources . Drug profiles featured in the report undergoes periodic review following a s tringent s et of proces s es to ens ure that all the profiles are updated with the lates t s et of information. Additionally, various dynamic tracking proces s es ens ure that the mos t recent developments are captured on a real time bas is . The report helps in identifying and tracking emerging players in the market and their portfolios , enhances decis ion making capabilities and helps to create effective counter s trategies to gain competitive advantage. Note*: Certain s ections in the report may be removed or altered bas ed on the availability and relevance of data. Scope - The report provides a s naps hot of the global therapeutic lands cape of Macular Edema - The report reviews pipeline therapeutics for Macular Edema by companies and univers ities /res earch ins titutes bas ed on information derived from company and indus try-s pecific s ources - The report covers pipeline products bas ed on various s tages of development ranging from pre-regis tration till dis covery and undis clos ed s tages - The report features des criptive drug profiles for the pipeline products which includes , product des cription, des criptive MoA, R& D brief, licens ing and collaboration details & other developmental activities - The report reviews key players involved Macular Edema therapeutics and enlis ts all their major and minor projects - The report as s es s es Macular Edema therapeutics bas ed on drug target, mechanis m of action (MoA), route of adminis tration (RoA) and molecule type - The report s ummarizes all the dormant and dis continued pipeline projects - The report reviews lates t news related to pipeline therapeutics for Macular Edema Reas ons to buy - Gain s trategically s ignificant competitor information, analys is , and ins ights to formulate effective R& D s trategies - Identify emerging players with potentially s trong product portfolio and create effective counter-s trategies to gain competitive advantage - Identify and unders tand important and divers e types of therapeutics under development for Macular Edema - Identify potential new clients or partners in the target demographic - Develop s trategic initiatives by unders tanding the focus areas of leading companies - Plan mergers and acquis itions effectively by identifying key players and it’s mos t promis ing pipeline therapeutics - Devis e corrective meas ures for pipeline projects by unders tanding Macular Edema
pipeline depth and focus of Indication therapeutics - Develop and des ign in-licens ing and out-licens ing s trategies by identifying pros pective partners with the mos t attractive projects to enhance and expand bus ines s potential and s cope - Modify the therapeutic portfolio by identifying dis continued projects and unders tanding the factors that drove them from pipeline Contents:
Table of Contents Table of Contents 2 Lis t of Tables 5 Lis t of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Macular Edema Overview 8 Therapeutics Development 9 Pipeline Products for Macular Edema - Overview 9 Macular Edema - Therapeutics under Development by Companies 10 Macular Edema - Pipeline Products Glance 12 Late Stage Products 12 Clinical Stage Products 13 Early Stage Products 14 Unknown Stage Products 15 Macular Edema - Products under Development by Companies 16 Macular Edema - Companies Involved in Therapeutics Development 17 ActiveSite Pharmaceuticals , Inc. 17 Ampio Pharmaceuticals , Inc. 18 Clears ide BioMedical, Inc. 19 Clonz Biotech Private Limited 20 Coherus BioSciences , Inc. 21 EyeGate Pharmaceuticals , Inc. 22 Mabion SA 23 Pfizer Inc. 24 Precis ion Ocular Ltd 25 Promedior, Inc. 26 Taiwan Lipos ome Company, Ltd. 27 Valeant Pharmaceuticals International, Inc. 28 Xbrane Biopharma AB 29 Macular Edema - Therapeutics As s es s ment 30 As s es s ment by Monotherapy Products 30 As s es s ment by Combination Products 31 As s es s ment by Target 32 As s es s ment by Mechanis m of Action 34 As s es s ment by Route of Adminis tration 36 As s es s ment by Molecule Type 38 Drug Profiles 40 (aflibercept + triamcinolone acetonide) - Drug Profile 40 Product Des cription 40 Mechanis m of Action 40 R& D Progres s 40 ACX-107 - Drug Profile 42 Product Des cription 42 Mechanis m of Action 42 R& D Progres s 42 ASPPDC-020 - Drug Profile 43 Product Des cription 43 Mechanis m of Action 43 R& D Progres s 43 BLO-021 - Drug Profile 44 Product Des cription 44 Mechanis m of Action 44 R& D Progres s 44 celecoxib - Drug Profile 45 Product Des cription 45 Mechanis m of Action 45 R& D Progres s 45 danazol - Drug Profile 47 Product Des cription 47 Mechanis m of Action 47 R& D Progres s 47 dexamethas one acetate - Drug Profile 48 Product Des cription 48 Mechanis m of Action 48 R& D Progres s 48 dexamethas one s odium phos phate SR - Drug Profile 50 Product Des cription 50 Mechanis m of Action 50 R& D Progres s 50
Drugs for Retinal Dis eas es - Drug Profile 51 Product Des cription 51 Mechanis m of Action 51 R& D Progres s 51 PRM-167 - Drug Profile 52 Product Des cription 52 Mechanis m of Action 52 R& D Progres s 52 ranibizumab bios imilar - Drug Profile 53 Product Des cription 53 Mechanis m of Action 53 R& D Progres s 53 ranibizumab bios imilar - Drug Profile 54 Product Des cription 54 Mechanis m of Action 54 R& D Progres s 54 ranibizumab bios imilar - Drug Profile 55 Product Des cription 55 Mechanis m of Action 55 R& D Progres s 55 ranibizumab bios imilar - Drug Profile 56 Product Des cription 56 Mechanis m of Action 56 R& D Progres s 56 triamcinolone acetonide - Drug Profile 57 Product Des cription 57 Mechanis m of Action 57 R& D Progres s 57 Macular Edema - Recent Pipeline Updates 59 Macular Edema - Dormant Projects 67 Macular Edema - Dis continued Products 68 Macular Edema - Product Development Miles tones 69 Featured News & Pres s Releas es 69 Apr 26, 2016: Clears ide Biomedical Announces Pos itive Preliminary Phas e 2 Res ults in Patients With Macular Edema As s ociated with Retinal Vein Occlus ion 69 Jan 05, 2016: Clears ide Biomedical Announces Pos itive Topline Data from Phas e 2 Clinical Trial for the Treatment of Macular Edema As s ociated with Non-Infectious Uveitis 69 Dec 14, 2015: Clears ide Biomedical Completes Enrollment in Phas e 2 Clinical Trial of CLS-TA for the Treatment of Retinal Vein Occlus ion Us ing Suprachoroidal Space Drug Adminis tration 70 Dec 07, 2015: Clears ide Biomedical, Inc. Enrolls Firs t Patient in Phas e 3 Clinical Trial of CLS-TA Us ing Suprachoroidal Drug Adminis tration 71 Oct 12, 2015: Clears ide Biomedical Completes Enrollment in Phas e 2 Clinical Trial of CLS-TA Us ing Suprachoroidal Space Drug Adminis tration 71 Jun 16, 2015: Clears ide Biomedical Announces Favorable End-of-Phas e 2 Review with the FDA 72 Mar 02, 2015: Clears ide Biomedical Initiates Phas e 2 Clinical Trial to Evaluate Reducing Treatment Vis its While Improving Outcomes in Macular Edema As s ociated with Retinal Vein Occlus ion 72 Appendix 74 Methodology 74 Coverage 74 Secondary Res earch 74 Primary Res earch 74 Expert Panel Validation 74 Contact Us 74 Dis claimer 75 Lis t of Tables Number of Products under Development for Macular Edema, H1 2016 9 Number of Products under Development by Companies , H1 2016 11 Comparative Analys is by Late Stage Development, H1 2016 12 Comparative Analys is by Clinical Stage Development, H1 2016 13 Comparative Analys is by Early Stage Development, H1 2016 14 Comparative Analys is by Unknown Stage Development, H1 2016 15 Products under Development by Companies , H1 2016 16 Macular Edema - Pipeline by ActiveSite Pharmaceuticals , Inc., H1 2016 17 Macular Edema - Pipeline by Ampio Pharmaceuticals , Inc., H1 2016 18 Macular Edema - Pipeline by Clears ide BioMedical, Inc., H1 2016 19 Macular Edema - Pipeline by Clonz Biotech Private Limited, H1 2016 20 Macular Edema - Pipeline by Coherus BioSciences , Inc., H1 2016 21 Macular Edema - Pipeline by EyeGate Pharmaceuticals , Inc., H1 2016 22 Macular Edema - Pipeline by Mabion SA, H1 2016 23 Macular Edema - Pipeline by Pfizer Inc., H1 2016 24 Macular Edema - Pipeline by Precis ion Ocular Ltd, H1 2016 25 Macular Edema - Pipeline by Promedior, Inc., H1 2016 26 Macular Edema - Pipeline by Taiwan Lipos ome Company, Ltd., H1 2016 27 Macular Edema - Pipeline by Valeant Pharmaceuticals International, Inc., H1 2016 28
Macular Edema - Pipeline by Xbrane Biopharma AB, H1 2016 29 As s es s ment by Monotherapy Products , H1 2016 30 As s es s ment by Combination Products , H1 2016 31 Number of Products by Stage and Target, H1 2016 33 Number of Products by Stage and Mechanis m of Action, H1 2016 35 Number of Products by Stage and Route of Adminis tration, H1 2016 37 Number of Products by Stage and Molecule Type, H1 2016 39 Macular Edema Therapeutics - Recent Pipeline Updates , H1 2016 59 Macular Edema - Dormant Projects , H1 2016 67 Macular Edema - Dis continued Products , H1 2016 68 Lis t of Figures Number of Products under Development for Macular Edema, H1 2016 9 Number of Products under Development by Companies , H1 2016 10 Comparative Analys is by Clinical Stage Development, H1 2016 13 Comparative Analys is by Early Stage Products , H1 2016 14 As s es s ment by Monotherapy Products , H1 2016 30 Number of Products by Targets , H1 2016 32 Number of Products by Stage and Targets , H1 2016 32 Number of Products by Mechanis m of Actions , H1 2016 34 Number of Products by Stage and Mechanis m of Actions , H1 2016 34 Number of Products by Routes of Adminis tration, H1 2016 36 Number of Products by Stage and Routes of Adminis tration, H1 2016 36 Number of Products by Molecule Types , H1 2016 38 Number of Products by Stage and Molecule Types , H1 2016 38
wis eguyreports .com / Phone (US) + 1-646-845-9349 (UK) +44 208 133 9349